Store
The World Market for Liquid Biopsy, 2023
Publication Date: December 29, 2022
Tags: Diagnostic Instruments, Genetic Diseases, Liquid Biopsy, Oncology and Cancer
Pages: 210
SKU: 22-048
Dramatic changes have occurred in the liquid biopsy market, necessitating a resource to provide perspective on the market opportunity. This new report from Kalorama assesses the liquid biopsy market now and in 2027.
The World Market for Liquid Biopsy, 2023 is a crucial resource for stakeholders in the healthcare and diagnostic industries. This report provides comprehensive insights into market dynamics, regional growth, and segment-specific forecasts, equipping you with the knowledge needed to navigate and succeed in this rapidly evolving market.
Report Highlights:
- Market Dynamics:
- Overview of the dramatic changes in the liquid biopsy market, highlighting the increasing acceptance and adoption of liquid biopsy tests.
- Discussion on how liquid biopsy serves as an alternative or complementary technique to traditional tissue biopsies and imaging in clinical oncology.
- Insights into the market’s resilience and growth, even during the COVID-19 pandemic, with numerous new product announcements and clinical studies.
- Comprehensive Coverage:
- Regional Markets:
- Detailed market analysis by region: North America, Europe, Asia, and the Rest of the World.
- Market Segments:
- The market for CTC-based liquid biopsy, ctDNA-based liquid biopsy, EV and exosome-based liquid biopsy, multi-analyte-based liquid biopsy, and other analytes, with growth forecasts to 2027.
- Regional Markets:
- Cancer Types:
- Market assessments for liquid biopsy by type of cancer: Breast, Lung, Colorectal, Ovarian, Prostate, Pan-Cancer, and other cancers.
- R&D and Market Availability:
- Overview of selected ctDNA-based liquid biopsy tests in development.
- Information on market-available CTC-based liquid biopsy tests and tests assessing multiple analytes as of 2021.
Market Applications:
- Clinical Oncology:
- Early detection and diagnosis/screening.
- Alternative testing methods when tissue biopsy is difficult or impossible, or when the primary site of metastatic disease is unknown.
- Therapy personalization and monitoring through molecular characterization of a patient’s disease, allowing clinicians to select optimal therapies and monitor efficacy.
- Disease monitoring to observe disease progression, tumor evolution, residual disease, and early detection of recurrence.
Table: Global Liquid Biopsy Market, by Geographic Region, 2022-2027 (in millions $)
| Region | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | CAGR ’22 – ’27 |
| North America | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Europe | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Asia Pacific | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Rest of World | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| WORLD | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
Source: Kalorama Information
For further details and to purchase directly, please contact us.
Table of Contents
Chapter One: Executive Summary
Introduction
Liquid Biopsy Technologies
Industry Structure
Liquid Biopsy Market Revenues and Forecast
- Figure 1-1: Market for Liquid Biopsy 2022-2027
- Figure 1-2: Global Liquid Biopsy Market by Geographic Region, 2022 (%)
- Table 1-1: Global Liquid Biopsy Market by Geographic Region, 2022-2027 $(M)
Chapter Two: Liquid Biopsy Technologies
Introduction
- Table 2-1: Comparison of Tissue and Liquid Biopsy
Current Major Liquid Biopsy Technologies
- Table 2-2: Advantages and Limitations of Major Liquid Biopsy Technologies
Chapter Three: Circulating Tumor DNA (ctDNA) Liquid Biopsy
Introduction
Advantages and Limitations of ctDNA in Liquid Biopsy
Current ctDNA-based Liquid Biopsy Tests
- Table 3-1: Selected Market-Available ctDNA-based Liquid Biopsy Tests, 2022Company/ Country
Biocartis
Biocept
Biodesix
CellMax Life
Circulogene
Diacarta
Epigenomics
Foundation Medicine (Roche)
Guardant Health
Inivata (Neogenomics)
LungLife AI
Myriad Genetics
NeoGenomics
OncoDNA
Personal Genomic Diagnostics
QIAGEN
Resolution Biosciences
Roche Diagnostics
Sysmex-Inostics
Tempus
ctDNA-based Liquid Biopsy Tests in Development
- Table 3-2: Selected ctDNA-based Liquid Biopsy Tests in Development, 2022
Exact Sciences
Freenome
GRAIL
Chapter Four: Circulating Tumor Cells (CTCs) Liquid Biopsy
Introduction
Challenges in the Development of CTC-based Liquid Biopsy Tests
CTC-based Liquid Biopsy Tests
- Table 4-1: Selected Market-Available CTC-based Liquid Biopsy Tests, 2022
Adaptive Biotechnologies
ANGLE
Biocept
CellMax Life
Epic Sciences
GILUPI
LungLife AI
Menarini-Silicon Biosystems
QIAGEN
Selected CTC-based Liquid Biopsy Tests in Development
- Table 4-2: Selected CTC-based Liquid Biopsy Tests in Development, 2022
Epic Sciences
Liquid Biotech USA
Chapter Five: Extracellular Vesicles and Other Liquid Biopsy
Introduction
Liquid Biopsy Tests Based on Extracellular Vesicles / Other Analytes
- Table 5-1: Selected Market-Available Liquid Biopsy Tests based on Extracellular Vesicles / Other Analytes, 2022
Aspira Women’s Health (formerly Vermillion)
Biodesix
Exosome Diagnostics
Hologic
MDxHealth
Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development
- Table 5-2: Selected Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development, 2022
Circulogene
OncoCyte
Resolution Biosciences
VolitionRx
Chapter Six: Multi-Analyte Liquid Biopsy Tests
Introduction
Liquid Biopsy Tests Based on Multiple Analytes
- Table 6-1: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2022
Biocept
Biodesix
Foundation Medicine (Roche)
LungLife AI
NeoGenomics
OncoDNA
Multiple Analyte-based Liquid Biopsy Tests in Development
- Table 6-2: Selected Multi Analyte-based Liquid Biopsy Tests in Development, 2022
Exact Sciences
Freenome
GRAIL
LungLife AI
Chapter Seven: Liquid Biopsy Tests for Research Use Only
Introduction
Liquid Biopsy Tests for Research Use Only
- Table 7-1: Selected Liquid Biopsy Tests for Research Use Only, 2022
Agena Bioscience
DiaCarta
Exosome Diagnostics
Guardant Health
Natera
QIAGEN
Chapter Eight: Liquid Biopsy Industry Analysis
Introduction
Tiers of Competition
- Table 8-1: Selected Participants in the Liquid Biopsy Market, 2022
Competitive Factors
Significant Market Trends
- Table 8-2: Significant Trends in the Liquid Biopsy Market, 2022
Personalized Medicine
Increasing Global Life Expectancy
New Liquid Biopsy Products
Increasing Accessibility of Genetic Testing
Regulatory Hurdles
Third-Party Payor Coverage
Demonstrated Clinical Utility
Incidence Rates of Specific Cancers
Competitors No Longer in the Liquid Biopsy Market
- Table 8-3: Summary of Companies That Have Exited the Liquid Biopsy Market
Chapter Nine: Liquid Biopsy Market
Market Overview
- Table 9-1: Global Liquid Biopsy Diagnostics Market Estimate by Region, 2022 (%)
- Figure 9-1: Global Liquid Biopsy Diagnostics Market Estimate by Region, 2022 (%)
Market Forecast
- Table 9-2: Global Liquid Biopsy Market Forecast by Region – North America, Europe, Asia Pacific, Rest of World, World ($ millions), 2022-2027
Chapter Ten: Market by Analyte
Circulating Tumor DNA
Market Overview
Applications
Technologies
Specimens
Revenue Forecast
- Table 10-1: Global Liquid Biopsy Market for ctDNA ($ millions), 2022-2027
Circulating Tumor Cells
Market Overview
Applications
Technologies
Specimens
Revenue Forecast
- Table 10-2: Global Liquid Biopsy Market for CTCs ($ millions), 2022-2027
Extracellular Vesicles and Other Analytes
Market Overview
Applications
Technologies
Specimens
Revenue Forecast
- Table 10-3: Global Liquid Biopsy Market for Extracellular Vesicles ($ millions), 2022-2027
Multiple Analytes
Market Overview
Revenue Forecast
- Table 10-4: Global Liquid Biopsy Market for Multiple Analytes ($ millions), 2022-2027
Chapter Eleven: Market by Application
Therapy Guidance and Monitoring
Market Overview
Revenue Forecast
- Table 11-1: Liquid Therapy for Therapy Guidance ($ millions), 2022-2027
Diagnosis/Screening
Market Overview
Revenue Forecast
- Table 11-2: Global Liquid Biopsy Market for Diagnosis and Screening ($ millions), 2022-2027
Disease Prognosis
Market Overview
Revenue Forecast
- Table 11-3: Global Liquid Biopsy Market for Disease Prognosis ($ millions), 2022-2027
Chapter Twelve: Market by Cancer Type
Breast Cancer
Market Overview
Revenue Forecast
- Table 12-1: Global Liquid Biopsy Market for Breast Cancer ($ millions), 2022-2027
Colorectal Cancer
Market Overview
Revenue Forecast
- Table 12-2: Global Liquid Biopsy Market for Colorectal Cancer ($ millions), 2022-2027
Lung Cancer
Market Overview
Revenue Forecast
- Table 12-3: Global Liquid Biopsy Market for Lung Cancer ($ millions), 2022-2027
Ovarian Cancer
Market Overview
Revenue Forecast
- Table 12-4: Global Liquid Biopsy Market for Ovarian Cancer ($ millions), 2022-2027
Prostate Cancer
Market Overview
Revenue Forecast
- Table 12-5: Global Liquid Biopsy Market for Prostate Cancer ($ millions), 2022-2027
Other Cancers
Market Overview
Revenue Forecast
- Table 12-6: Global Liquid Biopsy Market for Other Cancers ($ millions), 2022-2027
Pan-Cancer Tests
Market Overview
Revenue Forecast
- Table 12-7: Global Liquid Biopsy Market for Pan-Cancer Testing ($ millions), 2022-2027
Chapter Thirteen: Company Profiles
Companies in the Market
- Table 13-1 Companies in the Liquid Biopsy Market
Adaptive Biotechnologies
Agena Bioscience, Inc.
ANGLE, plc
Aspira Women’s Health
Biocartis Group NV
Biocept, Inc.
Biodesix
CellMax Life
Circulogene
DiaCarta, Inc.
Epic Sciences
Epigenomics AG
Exact Sciences
Exosome Diagnostics, Inc.
Foundation Medicine, Inc. (Roche)
Freenome, Inc.
GILUPI GmbH
GRAIL (Illumina)
Guardant Health, Inc.
Hologic
LungLife AI (formerly Cynvenio Biosystems)
Menarini-Silicon Biosystems, Spa
Myriad Genetics, Inc.
Natera, Inc.
NeoGenomics Laboratories, Inc.
Oncocyte Corporation
OncoDNA S.A.
Personal Genome Diagnostics
QIAGEN N.V.
Cell-free DNA Technologies
CTC Technologies
Exosome and miRNA Technologies
Resolution Biosciences (Agilent)
Roche Diagnostics
Sysmex-Inostics, Inc.
Tempus
VolitionRx
Related products
In Vitro Diagnostic (IVD) Trends and Market Update: November 2023
November 7, 2023
As in vitro diagnostic (IVD) testing returns to its vital role in healthcare, it remains a cornerstone in medical practice, providing crucial insights for physicians, from diagnosis to precision medicine. While COVID-19 testing sees a decline, it continues to influence total revenues for 2023. In this ever-changing landscape, characterized by new products, shifts in global…
Price range: $3,750.00 through $5,625.00
Histology and Cytology IVD Market Update, 2024
May 21, 2024
Histology and cytology have long been essential components of pathological laboratories, offering critical insights into cells, tissues, and organs. Through histopathological examinations, a variety of diseases, including cancer, can be accurately diagnosed. Physicians rely heavily on pathological information to determine treatment plans and prognoses.
Histology and Cytology IVD Market Update, 2024 provides an in-depth competitive analysis…
Price range: $5,000.00 through $7,875.00
Cell Therapy and Gene Therapy Disease Markets, 2023-2029
April 30, 2024
Explore the future of medicine with our in-depth report on cell therapy, gene therapy, and RNA therapy markets. Cell therapy and gene therapy represent a frontier in modern medicine, promising revolutionary treatments by treating the underlying genetic causes of disease and by genetically controlling the body’s immune system. Recent years have seen an increase in…
Price range: $5,000.00 through $7,875.00
